Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 33Recruiting 8Terminated 4Unknown 3Withdrawn 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Breast Neoplasms 1275Carcinoma, Non-Small-Cell Lung 783Neoplasms 767Colorectal Neoplasms 755Carcinoma, Hepatocellular 579Stomach Neoplasms 578Prostatic Neoplasms 501Lung Neoplasms 461Pancreatic Neoplasms 416Rectal Neoplasms 331Recurrence 312Neoplasm Metastasis 305Leukemia, Myeloid, Acute 289Multiple Myeloma 281Colonic Neoplasms 280Lymphoma 273Uterine Cervical Neoplasms 269Esophageal Neoplasms 267Ovarian Neoplasms 261Head and Neck Neoplasms 246Melanoma 240Precursor Cell Lymphoblastic Leukemia-Lymphoma 209Brain Neoplasms 195Lymphoma, Large B-Cell, Diffuse 184Nasopharyngeal Carcinoma 180Lymphoma, Non-Hodgkin 173Leukemia 173Liver Neoplasms 163Glioblastoma 158Urinary Bladder Neoplasms 153

Interventions

Dexamethasone 2pomalidomide 1isatuximab 1Technetium Tc 99m Pyrophosphate 1Technetium 1Lisaftoclax 1GTP Cyclohydrolase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Interventional × Amyloidosis × Clear all
NCT05066607 2024-03-06

IsAMYP

Intergroupe Francophone du Myelome

Phase 2 Unknown
46 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT04942067 2023-10-25

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Ascentage Pharma Group Inc.

Phase 1/2 Unknown
108 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma

NCT05951816 2023-07-19

A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

University of Tennessee Graduate School of Medicine

Phase 1 Unknown
35 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡